Affinity Asset Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Affinity Asset Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,000,000	Closed	-$18M	–	101
2024 Q3	$18M	Sell	1,000,000 -150,000	-13%	-$2.63M	2.46%	13
2024 Q2	$18.7M	Sell	1,150,000 -505,000	-31%	-$7.78M	2.15%	10
2024 Q1	$23.4M	Buy	1,655,000 +255,000	+18%	+$3.21M	2.89%	6
2023 Q4	$14.6M	Buy	1,400,000 +300,000	+27%	+$2.8M	2.67%	13
2023 Q3	$11.2M	Buy	+1,100,000	New	+$10.2M	3.16%	11

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's TEVA Position: Q1 2026 in Review

Affinity Asset Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 1,400,000 shares worth $42.2M. The position accounts for 2.18% of the portfolio, ranked #14.

Affinity Asset Advisors first reported a position in TEVA in Q2 2023 and has held it in 12 quarters since. The position peaked at $43.7M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Affinity Asset Advisors held 1,400,000 shares of Teva Pharmaceuticals worth $42.2M as of Q1 2026.
Affinity Asset Advisors left its Teva Pharmaceuticals share count unchanged in Q1 2026.
Teva Pharmaceuticals made up 2.18% of Affinity Asset Advisors's portfolio in Q1 2026, its #14 holding.
Affinity Asset Advisors first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Affinity Asset Advisors's Teva Pharmaceuticals position peaked at $43.7M in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.